Silk Road Medical Inc (SILK)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
SILK Chart
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago.
Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover
Silk stock skyrocketed Tuesday after Boston Scientific agreed to buy the medical devices company for $1.16 billion.
Silk Road Medical Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JM John Malone Amundi | 487,680 | $23,341 | $23,341 | - | - |
Silk Road Medical Inc (SILK) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Silk Road Medical Inc Profile
| - Industry | - Sector | Mr. Lucas W. Buchanan CEO | NASDAQ (NGS) Exchange | 82710M100 CUSIP |
| US Country | 474 Employees | - Last Dividend | - Last Split | 4 Apr 2019 IPO Date |
Overview
Silk Road Medical, Inc. is a pioneering medical device company based in the United States, specializing in innovative treatment solutions for carotid artery disease. Since its inception in 2007, the company has focused on developing and commercializing a distinct approach known as transcarotid artery revascularization (TCAR). With its headquarters in Sunnyvale, California, Silk Road Medical has been at the forefront of addressing the complications associated with traditional carotid artery disease treatments by introducing minimally invasive techniques that promise improved patient outcomes.
Products and Services
The company's portfolio comprises a series of advanced products designed to support the TCAR procedure, each contributing uniquely to the safety and effectiveness of the treatment:
- ENROUTE Transcarotid Neuroprotection System - This system facilitates direct access to the common carotid artery and establishes temporary blood flow reversal to protect the brain during the procedure. It is designed to minimize the risk of stroke by preventing debris from traveling towards the brain during stent placement.
- ENROUTE Transcarotid Stent System - Specifically engineered for transcarotid access, this system places a stent in the carotid artery to stabilize and keep the artery open, ensuring adequate blood flow to the brain post-procedure.
- ENHANCE Transcarotid Peripheral Access Kit - This kit facilitates initial access to the common carotid artery, ensuring that the procedure can be performed with precision and safety. It includes tools tailored for achieving stable entry points into the artery, setting the stage for a successful TCAR procedure.
- ENROUTE 0.014 Guidewire - Designed for atraumatic vessel navigation, this guidewire aids in smoothly crossing the target lesion and delivering interventional devices with minimized risk of complications. Its construction ensures reliability in reaching and effectively treating the affected area within the artery.
- ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter - A crucial part of the TCAR procedure, this rapid exchange balloon catheter is used to dilate the artery at the site of the blockage before stenting. This pre-treatment expansion is vital for optimal stent placement and effective long-term results.
